Mustang Bio Net Worth
Mustang Bio Net Worth Breakdown | MBIO |
Mustang Bio Net Worth Analysis
Mustang Bio's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Mustang Bio's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Mustang Bio's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Mustang Bio's net worth analysis. One common approach is to calculate Mustang Bio's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Mustang Bio's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Mustang Bio's net worth. This approach calculates the present value of Mustang Bio's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Mustang Bio's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Mustang Bio's net worth. This involves comparing Mustang Bio's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Mustang Bio's net worth relative to its peers.
Enterprise Value |
|
To determine if Mustang Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Mustang Bio's net worth research are outlined below:
| Mustang Bio generated a negative expected return over the last 90 days | |
| Mustang Bio has high historical volatility and very poor performance | |
| Mustang Bio has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (51.6 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Mustang Bio currently holds about 107.37 M in cash with (49.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.01. | |
| Mustang Bio has a frail financial position based on the latest SEC disclosures | |
| Latest headline from seekingalpha.com: Mustang Bio files to sell common stock, warrants |
Mustang Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Mustang Bio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Mustang Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Mustang Bio Target Price Consensus
Mustang target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Mustang Bio's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Buy |
Most Mustang analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Mustang stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Mustang Bio, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationMustang Bio Target Price Projection
Mustang Bio's current and average target prices are 5.55 and 17.25, respectively. The current price of Mustang Bio is the price at which Mustang Bio is currently trading. On the other hand, Mustang Bio's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Mustang Bio Market Quote on 20th of January 2025
Target Price
Analyst Consensus On Mustang Bio Target Price
Know Mustang Bio's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Mustang Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mustang Bio backward and forwards among themselves. Mustang Bio's institutional investor refers to the entity that pools money to purchase Mustang Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jamison Private Wealth Management Inc | 2024-09-30 | 15 K | Tower Research Capital Llc | 2024-09-30 | 11 K | Jump Financial Llc | 2024-09-30 | 10.8 K | Fmr Inc | 2024-09-30 | 10.2 K | Wells Fargo & Co | 2024-09-30 | 9 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 8.9 K | Macquarie Group Ltd | 2024-09-30 | 8 K | Ubs Group Ag | 2024-09-30 | 5.6 K | Harbour Investments, Inc. | 2024-09-30 | 3.8 K | Geode Capital Management, Llc | 2024-09-30 | 245.5 K | Citadel Advisors Llc | 2024-09-30 | 112.8 K |
Follow Mustang Bio's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.28 M.Market Cap |
|
Project Mustang Bio's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.34) | (3.18) | |
| Return On Capital Employed | (24.60) | (23.37) | |
| Return On Assets | (3.34) | (3.18) | |
| Return On Equity | (482.46) | (458.33) |
When accessing Mustang Bio's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Mustang Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Mustang Bio's profitability and make more informed investment decisions.
Evaluate Mustang Bio's management efficiency
Mustang Bio has return on total asset (ROA) of (0.9652) % which means that it has lost $0.9652 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (11.9131) %, meaning that it created substantial loss on money invested by shareholders. Mustang Bio's management efficiency ratios could be used to measure how well Mustang Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of the 20th of January 2025, Return On Tangible Assets is likely to grow to -3.18. In addition to that, Return On Capital Employed is likely to grow to -23.37. At this time, Mustang Bio's Net Tangible Assets are very stable compared to the past year. As of the 20th of January 2025, Non Current Assets Total is likely to grow to about 8.8 M, while Total Assets are likely to drop about 19.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.02 | 0.02 | |
| Tangible Book Value Per Share | 0.02 | 0.02 | |
| Enterprise Value Over EBITDA | (10.81) | (11.35) | |
| Price Book Value Ratio | 4.2 K | 4.5 K | |
| Enterprise Value Multiple | (10.81) | (11.35) | |
| Price Fair Value | 4.2 K | 4.5 K | |
| Enterprise Value | 2.3 B | 2.2 B |
The operational strategies employed by Mustang Bio management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mustang Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mustang Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Mustang Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mustang Bio Corporate Filings
8K | 17th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
S1 | 15th of January 2025 Report filed by companies planning on going public to register their securities with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
F3 | 3rd of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
| 6th of December 2024 Other Reports | ViewVerify |
Mustang Bio Earnings Estimation Breakdown
The calculation of Mustang Bio's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Mustang Bio is estimated to be -7.625 with the future projection ranging from a low of -7.625 to a high of -7.625. Please be aware that this consensus of annual earnings estimates for Mustang Bio is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-7.62 Lowest | Expected EPS | -7.62 Highest |
Mustang Bio Earnings Projection Consensus
Suppose the current estimates of Mustang Bio's value are higher than the current market price of the Mustang Bio stock. In this case, investors may conclude that Mustang Bio is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Mustang Bio's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 1 | 60.61% | -0.3546 | -7.625 | -66.5 |
Mustang Bio Earnings per Share Projection vs Actual
Actual Earning per Share of Mustang Bio refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Mustang Bio predict the company's earnings will be in the future. The higher the earnings per share of Mustang Bio, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Mustang Bio Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Mustang Bio, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Mustang Bio should always be considered in relation to other companies to make a more educated investment decision.Mustang Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Mustang Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-12 | 2024-09-30 | -0.13 | -0.04 | 0.09 | 69 | ||
2024-08-13 | 2024-06-30 | -0.14 | -0.3546 | -0.2146 | 153 | ||
2024-05-15 | 2024-03-31 | -0.87 | -0.4613 | 0.4087 | 46 | ||
2024-03-11 | 2023-12-31 | -1.33 | -0.86 | 0.47 | 35 | ||
2023-11-14 | 2023-09-30 | -1.27 | -1.4 | -0.13 | 10 | ||
2023-08-14 | 2023-06-30 | -1.81 | -2.0 | -0.19 | 10 | ||
2023-05-12 | 2023-03-31 | -3.01 | -2.06 | 0.95 | 31 | ||
2023-03-29 | 2022-12-31 | -2.89 | -2.7 | 0.19 | 6 | ||
2022-11-14 | 2022-09-30 | -0.2 | -0.18 | 0.02 | 10 | ||
2022-08-11 | 2022-06-30 | -0.21 | -0.19 | 0.02 | 9 | ||
2022-05-12 | 2022-03-31 | -0.18 | -0.2 | -0.02 | 11 | ||
2022-03-23 | 2021-12-31 | -0.19 | -0.22 | -0.03 | 15 | ||
2021-11-12 | 2021-09-30 | -0.18 | -0.19 | -0.01 | 5 | ||
2021-08-16 | 2021-06-30 | -0.2 | -0.16 | 0.04 | 20 | ||
2021-05-14 | 2021-03-31 | -0.19 | -0.19 | 0.0 | 0 | ||
2021-03-24 | 2020-12-31 | -0.21 | -0.32 | -0.11 | 52 | ||
2020-11-06 | 2020-09-30 | -0.25 | -0.23 | 0.02 | 8 | ||
2020-08-10 | 2020-06-30 | -0.27 | -0.32 | -0.05 | 18 | ||
2020-05-11 | 2020-03-31 | -0.31 | -0.28 | 0.03 | 9 | ||
2020-03-16 | 2019-12-31 | -0.26 | -0.42 | -0.16 | 61 | ||
2019-11-12 | 2019-09-30 | -0.26 | -0.25 | 0.01 | 3 | ||
2019-08-09 | 2019-06-30 | -0.25 | -0.29 | -0.04 | 16 | ||
2019-05-10 | 2019-03-31 | -0.36 | -0.34 | 0.02 | 5 | ||
2019-03-18 | 2018-12-31 | -0.27 | -0.44 | -0.17 | 62 | ||
2018-11-13 | 2018-09-30 | -0.2 | -0.28 | -0.08 | 40 | ||
2018-08-13 | 2018-06-30 | -0.25 | -0.19 | 0.06 | 24 | ||
2018-05-14 | 2018-03-31 | -0.23 | -0.24 | -0.01 | 4 | ||
2018-03-29 | 2017-12-31 | -0.24 | -0.61 | -0.37 | 154 |
Mustang Bio Corporate Management
| Kerry BBA | VP Operations | Profile | |
| Lynn MS | VP Affairs | Profile | |
| Eliot CPA | Interim Officer | Profile | |
| Richard MS | Head Development | Profile | |
| Matthew JD | VP Counsel | Profile | |
| Bruce MD | Senior Development | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mustang Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Mustang Stock, please use our How to Invest in Mustang Bio guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mustang Bio. If investors know Mustang will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mustang Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mustang Bio is measured differently than its book value, which is the value of Mustang that is recorded on the company's balance sheet. Investors also form their own opinion of Mustang Bio's value that differs from its market value or its book value, called intrinsic value, which is Mustang Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mustang Bio's market value can be influenced by many factors that don't directly affect Mustang Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mustang Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mustang Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mustang Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.